The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) hit a new 52-week low and has $1.85 target or 8.00% below today’s $2.01 share price. The 7 months bearish chart indicates high risk for the $95.06 million company. The 1-year low was reported on Mar, 25 by Barchart.com. If the $1.85 price target is reached, the company will be worth $7.60 million less. The stock decreased 6.07% or $0.13 during the last trading session, reaching $2.01. About 504,243 shares traded or 20.45% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 19.12% since March 25, 2018 and is downtrending. It has underperformed by 23.49% the S&P500. Some Historical ADMP News: 06/03/2018 ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON DATA PRESENTED AT THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI) JOINT CONGRESS WITH THE WORLD ALLERGY ORGANIZATION; 06/03/2018 – Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and lmmunology (AAAAI) Joint Congress With the World Allergy Organization; 15/03/2018 – Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update; 06/03/2018 – Adamis Pharmaceuticals Provides Update on Data Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Join; 22/04/2018 – DJ Adamis Pharmaceuticals Corporation, Inst Holders, 1Q 2018 (ADMP); 08/03/2018 – Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syring; 08/03/2018 – Adamis Pharmaceuticals Announces Publication of a New Human Factors Study Comparing Its Symjepi™ Epinephrine Prefilled Syringe to the Market Leading Product in the Annals of Allergy, Asthma and lmmunology
Dsam Partners Llp increased Anthem Inc (ANTM) stake by 14.89% reported in 2018Q4 SEC filing. Dsam Partners Llp acquired 16,611 shares as Anthem Inc (ANTM)’s stock rose 0.44%. The Dsam Partners Llp holds 128,158 shares with $33.66 million value, up from 111,547 last quarter. Anthem Inc now has $76.18B valuation. The stock decreased 1.79% or $5.39 during the last trading session, reaching $296.12. About 379,277 shares traded. Anthem, Inc. (NYSE:ANTM) has risen 26.09% since March 25, 2018 and is uptrending. It has outperformed by 21.72% the S&P500. Some Historical ANTM News: 23/05/2018 – ANTHEM SEES ACQUISITION BOOSTING EARNINGS IN 2019; 24/05/2018 – Trump Says NFL Owners’ Anthem Protest Ban Doesn’t Go Far Enough; 23/05/2018 – N.F.L. Teams Will Be Fined for Players’ Anthem Kneeling; 23/05/2018 – ABC6: #BREAKING: #NFL implements standing for Anthem policy, players have option of staying in locker room…; 09/03/2018 – Haeggquist & Eck Investigates Anthem Directors and Officers for Breach of Fiduciary Duty Regarding Failed CIGNA Merger; 25/04/2018 – Anthem 1Q EPS $4.99; 15/05/2018 – THIRD POINT BOOSTED DOV, ANTM, WP, FB, LEN IN 1Q: 13F; 01/05/2018 – FITCH AFFIRMS ANTHEM’S ‘A+’ IFS RATING; MAINTAINS NEGATIVE OUTL; 17/05/2018 – Diageo Launches New American Anthem Vodka; 26/04/2018 – ANTHEM INC ANTM.N : JP MORGAN RAISES TARGET PRICE TO $287 FROM $261
Dsam Partners Llp decreased Seaworld Entmt Inc (NYSE:SEAS) stake by 479,459 shares to 441,123 valued at $9.74 million in 2018Q4. It also reduced Diamondback Energy Inc (NASDAQ:FANG) stake by 10,000 shares and now owns 20,000 shares. Alteryx Inc was reduced too.
More news for Anthem, Inc. (NYSE:ANTM) were recently published by: Benzinga.com, which released: “Diplomat Pharmacy’s Valuation Presents Value To A Strategic Buyer, Raymond James Says In Upgrade (NYSE:DPLO) – Benzinga” on March 21, 2019. 247Wallst.com‘s article titled: “Morgan Stanley Picks 30 Stocks for 2021 – 24/7 Wall St.” and published on March 15, 2019 is yet another important article.
Among 11 analysts covering Anthem (NYSE:ANTM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Anthem had 18 analyst reports since November 1, 2018 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $368 target in Friday, March 8 report. Barclays Capital maintained Anthem, Inc. (NYSE:ANTM) on Friday, March 8 with “Buy” rating. The stock of Anthem, Inc. (NYSE:ANTM) has “Outperform” rating given on Thursday, November 1 by BMO Capital Markets. The rating was maintained by Cantor Fitzgerald on Tuesday, December 4 with “Overweight”. The stock of Anthem, Inc. (NYSE:ANTM) has “Buy” rating given on Thursday, February 21 by Morgan Stanley. The rating was maintained by Stephens with “Buy” on Wednesday, March 6. The company was maintained on Thursday, November 1 by Credit Suisse. The stock has “Neutral” rating by Citigroup on Tuesday, November 6. The rating was maintained by Cantor Fitzgerald on Thursday, March 7 with “Buy”. The rating was maintained by Jefferies with “Buy” on Monday, December 3.
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $95.06 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.
Among 3 analysts covering Adamis Pharmaceuticals (NASDAQ:ADMP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Adamis Pharmaceuticals had 5 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Tuesday, March 19 by Maxim Group. The firm earned “Neutral” rating on Monday, November 12 by FBR Capital. The stock has “Hold” rating by FBR Capital on Monday, March 18. The company was maintained on Tuesday, March 19 by Raymond James.
More notable recent Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news were published by: Seekingalpha.com which released: “Adamis Pharmaceuticals: Refused, Accepted, Missed, And Predictable – Seeking Alpha” on March 21, 2019, also Nasdaq.com with their article: “Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release – Nasdaq” published on March 14, 2019, Seekingalpha.com published: “Midday movers and shakers – Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Seeking Alpha” on March 05, 2019. More interesting news about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) were released by: Globenewswire.com and their article: “Adamis Provides Regulatory Update on Sublingual Tadalafil – GlobeNewswire” published on February 26, 2019 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 02/27/2019: SGYP, BHC, TNDM, ADMP, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: February 27, 2019.